Press release
SGLT2 Inhibitors Market is growing at a CAGR of 6.9% in the forecast period (2025-2034)
SGLT2 Inhibitors Market
๐๐๐ซ๐ค๐๐ญ ๐๐๐๐ข๐ง๐ข๐ญ๐ข๐จ๐ง:
SGLT2 inhibitors are a new class of oral drugs used for managing type 2 diabetes, including options like dapagliflozin, canagliflozin, empagliflozin, and more. It functions by stopping the kidneys from taking glucose back into the bloodstream. It inhibits these proteins and assists the kidneys in reducing blood glucose levels. The body eliminates the surplus glucose in the bloodstream through urine.
๐๐๐ญ ๐๐ฑ๐๐ฅ๐ฎ๐ฌ๐ข๐ฏ๐ ๐๐๐ฆ๐ฉ๐ฅ๐ ๐๐๐ ๐๐ฌ ๐จ๐ ๐๐ก๐ข๐ฌ ๐๐๐ฉ๐จ๐ซ๐ญ:
https://www.polarismarketresearch.com/industry-analysis/sglt2-inhibitors-market/request-for-sample
๐๐ซ๐จ๐ฐ๐ญ๐ก ๐๐ซ๐ข๐ฏ๐๐ซ๐ฌ ๐๐ง๐ ๐๐ฉ๐ฉ๐จ๐ซ๐ญ๐ฎ๐ง๐ข๐ญ๐ข๐๐ฌ:
โข The growing elderly population globally is adding to the rising incidence of diabetes and associated health issues. Due to factors related to aging, older adults are at an increased risk of developing type 2 diabetes, leading to a higher demand for SGLT2 inhibitors.
โข The growth of the market is affected by the authorization of new medications and widened indications by regulatory agencies like the FDA and EMA. SGLT2 inhibitors, recognized for their medical uses, have received expanded approval for more indications, such as type 2 diabetes, heart failure, and chronic kidney disease.
๐๐๐ฒ ๐๐ฅ๐๐ฒ๐๐ซ๐ฌ:
In this extremely competitive market, major rivals constantly innovate and differentiate their products in an effort to take the lead in the market.
Here is the list of the leading companies operating in the SGLT2 inhibitors market:
โข AstraZeneca
โข Boehringer Ingelheim International GmbH
โข Bristol-Myers Squibb Company
โข Eli Lilly and Company
โข Glenmark Pharmaceuticals Ltd.
โข Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals, Inc.)
โข Lexicon Pharmaceuticals, Inc.
โข Merck & Co., Inc.
โข Sanofi
โข TheracosBio, LLC
๐๐๐ช๐ฎ๐๐ฌ๐ญ ๐๐จ๐ซ ๐ ๐๐ข๐ฌ๐๐จ๐ฎ๐ง๐ญ ๐จ๐ง ๐ญ๐ก๐ข๐ฌ ๐๐๐ฉ๐จ๐ซ๐ญ ๐๐๐๐จ๐ซ๐ ๐๐ฎ๐ซ๐๐ก๐๐ฌ๐:
https://www.polarismarketresearch.com/industry-analysis/sglt2-inhibitors-market/request-for-discount-pricing
๐๐๐ ๐ฆ๐๐ง๐ญ๐๐ญ๐ข๐จ๐ง ๐๐ฏ๐๐ซ๐ฏ๐ข๐๐ฐ:
๐๐ฒ ๐๐ง๐๐ข๐๐๐ญ๐ข๐จ๐ง ๐๐ฎ๐ญ๐ฅ๐จ๐จ๐ค
โข Cardiovascular
โข Chronic Kidney Disease (CKD)
โข Type 2 Diabetes
โข Others
๐๐ฒ ๐๐ซ๐ฎ๐ ๐๐ฎ๐ญ๐ฅ๐จ๐จ๐ค
โข Farxiga (Dapagliflozin)
โข Inpefa (Sotagliflozin)
โข Invokana (Canagliflozin)
โข Jardiance (Empagliflozin)
โข Qtern (Dapagliflozin/Saxagliptin)
โข Other SGLT2 Inhibitors
๐๐ฒ ๐๐ข๐ฌ๐ญ๐ซ๐ข๐๐ฎ๐ญ๐ข๐จ๐ง ๐๐ก๐๐ง๐ง๐๐ฅ ๐๐ฎ๐ญ๐ฅ๐จ๐จ๐ค
โข Hospital Pharmacies
โข Online Pharmacies
โข Retail Pharmacies
๐๐ฒ ๐๐๐ ๐ข๐จ๐ง๐๐ฅ ๐๐ฎ๐ญ๐ฅ๐จ๐จ๐ค
โข North America
โข Europe
โข Asia Pacific
โข Latin America
โข Middle East & Africa
๐๐ง๐ช๐ฎ๐ข๐ซ๐ ๐ฆ๐จ๐ซ๐ ๐๐๐จ๐ฎ๐ญ ๐ญ๐ก๐ข๐ฌ ๐๐๐ฉ๐จ๐ซ๐ญ ๐๐๐๐จ๐ซ๐ ๐๐ฎ๐ซ๐๐ก๐๐ฌ๐:
https://www.polarismarketresearch.com/industry-analysis/sglt2-inhibitors-market/inquire-before-buying
๐๐๐๐๐ ๐๐ง๐ก๐ข๐๐ข๐ญ๐จ๐ซ๐ฌ ๐๐๐ซ๐ค๐๐ญ ๐๐๐ฉ๐จ๐ซ๐ญ ๐๐ข๐ ๐ก๐ฅ๐ข๐ ๐ก๐ญ๐ฌ:
โข In 2024, the type 2 diabetes segment accounted for the largest revenue share in the SGLT2 inhibitors market. Urbanization often leads to lifestyle changes characterized by decreased physical activity, increased consumption of processed foods, and higher stress levels. These factors contribute to the rising prevalence of obesity and type 2 diabetes, significantly driving the SGLT2 inhibitors market.
โข The online pharmacies segment is growing at the highest CAGR during the forecast period. Online pharmacies often offer competitive pricing and discounts on medications as a result of reduced overhead costs associated with online operations.
โข In 2024, North America SGLT2 inhibitors market accounted for the largest market due to the increasing chronic stress and poor mental. Additionally, the increasing prevalence of diabetes patients in North America has led to a higher demand for SGLT2 inhibitors in the region.
โข Asia Pacific accounted for the fastest growth in the market. Governments in the region are increasingly investing in healthcare infrastructure and initiatives to enhance access and quality. These efforts support pharmaceutical markets and the adoption of medications like SGLT2 inhibitors.
โข The global key market players include AstraZeneca; Boehringer Ingelheim International GmbH; Bristol-Myers Squibb Company; Eli Lilly and Company; Glenmark Pharmaceuticals Ltd.; Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals, Inc.); Lexicon Pharmaceuticals, Inc.; Merck & Co., Inc.; Sanofi; and TheracosBio, LLC.
๐๐๐ฅ๐๐ญ๐๐ ๐๐๐ฉ๐จ๐ซ๐ญ:
๐๐๐ฅ๐๐ซ๐๐๐ข๐จ๐ฅ๐จ๐ ๐ฒ ๐๐จ๐๐ญ๐ฐ๐๐ซ๐ ๐๐๐ซ๐ค๐๐ญ
https://www.polarismarketresearch.com/industry-analysis/teleradiology-software-market
๐๐๐ฅ๐ฅ ๐๐ซ๐จ๐๐๐ฌ๐ฌ๐ข๐ง๐ ๐๐ง๐ฌ๐ญ๐ซ๐ฎ๐ฆ๐๐ง๐ญ ๐๐๐ซ๐ค๐๐ญ
https://www.polarismarketresearch.com/industry-analysis/cell-processing-instruments-market
๐๐ข๐ฌ๐ฉ๐จ๐ฌ๐๐๐ฅ๐ ๐๐ง๐๐จ๐ฌ๐๐จ๐ฉ๐๐ฌ ๐๐๐ซ๐ค๐๐ญ
https://www.polarismarketresearch.com/industry-analysis/disposable-endoscopes-market
๐๐๐๐ข๐๐๐ฅ ๐๐๐ฅ๐๐ฉ๐ซ๐๐ฌ๐๐ง๐๐ ๐๐จ๐๐จ๐ญ๐ฌ ๐๐๐ซ๐ค๐๐ญ
https://www.polarismarketresearch.com/industry-analysis/medical-telepresence-robots-market
๐๐จ๐ฅ๐ ๐๐ฅ๐๐ฌ๐ฆ๐ ๐๐๐ซ๐ค๐๐ญ
https://www.polarismarketresearch.com/industry-analysis/cold-plasma-market
Contact:
Likhil G
8 The Green Ste 19824,
Dover, DE 19901,
United States
Phone: +1-929 297-9727
Email: sales@polarismarketresearch.com
Web: https://www.polarismarketresearch.com
Follow Us: LinkedIn | Twitter
About Polaris Market Research & Consulting, Inc:
Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for PMR's clientele spread across different enterprises. We at Polaris are obliged to serve PMR's diverse customer base present across the industries of healthcare, technology, semiconductors, and chemicals among various other industries present around the world. We strive to provide PMR's customers with updated information on innovative technologies, high-growth markets, emerging business environments, and the latest business-centric applications, thereby helping them always to make informed decisions and leverage new opportunities. Adept with a highly competent, experienced, and extremely qualified team of experts comprising SMEs, analysts, and consultants, we at Polaris endeavor to deliver value-added business solutions to PMR's customers.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release SGLT2 Inhibitors Market is growing at a CAGR of 6.9% in the forecast period (2025-2034) here
News-ID: 3740131 • Views: โฆ
More Releases from Polaris Market Research & Consulting
Granite Market Projected to Reach USD 6.63 Billion by 2034, Growing at a CAGR of โฆ
Polaris Market Research has released new insights into the Granite market, highlighting key developments, evolving trends, and growth prospects across major regions and segments. The report delivers an in-depth analysis of market dynamics, competitive shifts, and strategic outlooks to support informed decision-making for businesses and investors.
Market at a Glance
In 2024, the market was valued at USD 3.99 billion and is anticipated to grow to USD 6.63 Billion by 2034. Itโฆ
Molecular Diagnostics for Sexually Transmitted Diseases Market to Reach USD 7.85 โฆ
Polaris Market Research announces the release of its latest study on the Molecular Diagnostics For Sexually Transmitted Diseases market. It offers comprehensive insights into all the key market aspects, including industry trends, market dynamics, competitive landscape, and strategic developments. The report is designed to help stakeholders make strategic decisions in the rapidly evolving market landscape.
According to the findings, the market stood at 3.82 billion in 2024 and is expected toโฆ
Higher Alpha Olefins Market Projected to Hit USD 20.01 Billion by 2034, Expandin โฆ
Polaris Market Research announces the release of its latest study on the Higher Alpha Olefins market. It offers comprehensive insights into all the key market aspects, including industry trends, market dynamics, competitive landscape, and strategic developments. The report is designed to help stakeholders make strategic decisions in the rapidly evolving market landscape.
According to the findings, the market stood at 10.39 billion in 2024 and is expected to reach 20.01 billionโฆ
Direct Oral Anticoagulants (DOACs) Device Market to Reach USD 64.83 Billion by 2 โฆ
Polaris Market Research announces the release of its latest study on the Direct Oral Anticoagulants (DOACs) Device market. It offers comprehensive insights into all the key market aspects, including industry trends, market dynamics, competitive landscape, and strategic developments. The report is designed to help stakeholders make strategic decisions in the rapidly evolving market landscape.
According to the findings, the market stood at 31.67 billion in 2024 and is expected to reachโฆ
More Releases for SGLT2
SGLT2 Inhibitors Market to Accelerate Through 2034 with Expanding Indications an โฆ
Sodium-glucose co-transporter 2 (SGLT2) inhibitors have redefined the treatment paradigm for type 2 diabetes and are rapidly gaining traction across cardio-renal-metabolic diseases. Initially developed for glycemic control, this novel drug class has shown remarkable benefits in reducing cardiovascular and renal risks, propelling it beyond diabetic care into broader chronic disease management.
DelveInsight's latest report, "SGLT2 Inhibitors - Market Size, Target Population, Competitive Landscape & Market Forecast - 2034," offers a deepโฆ
Prominent Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Trend for 202 โฆ
What Are the Projected Growth and Market Size Trends for the Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market?
In the past few years, the market size for sodium glucose cotransporter 2 (SGLT2) inhibitors has seen a robust growth. From $10.17 billion in 2024, it is projected to expand to $11.07 billion in 2025, experiencing an 8.8% compound annual growth rate (CAGR). This upward trend during the historical time frame isโฆ
SGLT2 Inhibitors Market to Witness Huge Growth by 2032
The SGLT2 Inhibitors Market 2024 Report makes available the current and future technical and financial analysis of the industry. It is one of the most comprehensive and important additions to the USD Analytics archive of market research studies. It offers detailed research and analysis of key aspects of the global SGLT2 Inhibitors market. This global report explores the key factors affecting the growth of the dynamic SGLT2 Inhibitors market, includingโฆ
SGLT2 Inhibitor Market Analysis and Future Prospects for 2030
The world of the sglt2 inhibitor market is a complex and ever-evolving landscape, shaped by consumer demands and technological advancements. In this report, we delve into the depths of this market to provide a profound and comprehensive analysis, catering to a diverse audience that includes manufacturers, suppliers, distributors, and investors. Our primary goal is to empower industry stakeholders with invaluable insights to make informed decisions in a rapidly changing environment.โฆ
EU SGLT2 Inhibitor Market 2023 Share, Size, Key Players, Revenue Analysis | Prud โฆ
The EU SGLT2 Inhibitor Market 2023 Report makes available the current and forthcoming technical and financial details of the industry. It is one of the most comprehensive and important additions to the Prudent Markets archive of market research studies. It offers detailed research and analysis of key aspects of the global EU SGLT2 Inhibitor market. This report explores all the key factors affecting the growth of the global EU SGLT2โฆ
SGLT2 Inhibitors Treatment Market Current and Future Industry Landscape Analysis โฆ
SGLT2 Inhibitors Treatment market is looking forward to grow at a higher rate in the forecast period of 2021-2031. SGLT2 Inhibitors help in reabsorption of glucose from the kidney leading to low blood glucose level.
SGLT 2 inhibitors is said to grow the market in the near future as the consumption of the antidiabetics drugs is taking a spike. These have high consumption rate as the prevalence of type 2 diabetesโฆ
